A Chinese medicine composition and its use in preparing a medicine for treating / preventing chronic obstructive pulmonary disease
By using traditional Chinese medicine raw materials such as mulberry white bark, dandelion, scutellaria baicalensis, qianhu, qianhu and dilong, combined with heating extraction and silica gel column elution technology, a simple and effective traditional Chinese medicine composition was prepared, which solved the existing technology The complex problems of the prescription have significantly improved the effectiveness of treating and preventing bronchitis and chronic obstructive pulmonary diseases.
Patent Information
- Application Number
- CN202310427965.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-04-20
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2043-04-20
AI Technical Summary
The traditional Chinese medicine prescriptions for treating or preventing chronic obstructive pulmonary diseases in the prior art are complex, requiring multiple medicines to be combined, and there is a lack of simple and effective prescription solutions.
Using Chinese medicine raw materials such as mulberry white bark, dandelion, scutellaria baicalensis, tangerine peel, etc., combined with Qianhu and Dilong, the Chinese medicine composition is prepared by heating extraction and silica gel column elution, which significantly improves the effect of treating and preventing bronchitis. and extend to the treatment of chronic obstructive pulmonary disease.
It provides a Chinese medicine composition with simple prescriptions, no valuable drugs or toxic drugs, which has significant effects on the treatment and prevention of bronchitis and chronic obstructive pulmonary diseases. It has high clinical application value and low technical risk.
Smart Images

Figure BDA0004189264610000081 
Figure BDA0004189264610000111 
Figure BDA0004189264610000112
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of traditional Chinese medicines, and in particular to a traditional Chinese medicine composition and application thereof in preparing a medicine for treating and / or preventing chronic obstructive pulmonary disease. Background Art
[0002] Chronic obstructive pulmonary disease is a common chronic disease characterized by chronic bronchitis and / or emphysema with airflow obstruction, which can further develop into cor pulmonale and respiratory failure. It is associated with abnormal inflammatory reactions to harmful gases and particles, and usually has high disability and mortality rates. Therefore, it is of great clinical significance to provide a drug that can treat or prevent chronic bronchitis and further treat or prevent chronic obstructive pulmonary disease.
[0003] Chinese invention patent 201310693698.5 discloses a Chinese medicine for treating chronic obstructive pulmonary disease, characterized in that the raw materials are composed of 10-14% calamus, 8-12% schizonepeta, 6-10% white mulberry, 2-6% coltsfoot, 5-7% scutellariae, 2-6% white mustard, 2-6% coix seed, 5-7% terminalia, 6-10% galangal, 5-7% trichosanthes, 2-6% pubescens, 6-10% cuscuta, 2-5% scutellariae, 2-6% scutellariae, 2-6% fangji, 6-10% belamcanda, soak the above raw materials in water, decoct and remove the residue to obtain filtered juice. The invention has low cost, no toxic side effects, and high efficacy in treating chronic obstructive pulmonary disease.
[0004] Although Chinese invention patent 201310693698.5 discloses a Chinese medicine for treating chronic obstructive pulmonary disease, its formula is complex and requires compounding of multiple medicines. Therefore, it would be of great clinical significance to provide a medicine with a simple formula that can treat or prevent chronic bronchitis and further treat or prevent chronic obstructive pulmonary disease. Summary of the invention
[0005] In order to overcome at least one of the technical problems existing in the prior art, the present invention provides a traditional Chinese medicine composition.
[0006] The above technical problems to be solved by the present invention are achieved through the following technical solutions:
[0007] A traditional Chinese medicine composition comprises the following raw material components: mulberry bark, dandelion, scutellaria baicalensis, golden lock and tangerine peel.
[0008] The inventors have found in their research that a traditional Chinese medicine composition prepared with mulberry bark, dandelion, scutellaria baicalensis, golden lock and tangerine peel as raw materials has the effect of treating and / or preventing bronchitis.
[0009] Preferably, the Chinese medicine composition comprises the following raw material components in parts by weight:
[0010] 15-20 parts of mulberry bark; 15-20 parts of dandelion; 12-18 parts of scutellaria; 25-35 parts of golden lock; 8-10 parts of dried orange peel;
[0011] Most preferably, the Chinese medicine composition comprises the following raw material components in parts by weight:
[0012] 18 parts of Morus alba bark; 18 parts of Herba Taraxaci; 15 parts of Radix Scutellariae; 30 parts of Rhizoma Chrysanthemi Indici; 9 parts of Pericarpium Citri Reticulatae.
[0013] Preferably, the Chinese medicine composition further comprises Peucedanum peucedanum and / or Pheretima lum.
[0014] Most preferably, the Chinese medicine composition further comprises Peucedanum peucedanum and Pheretima lum.
[0015] The inventors surprisingly found in the research that by adding Peucedanum chinense and Pheretima to Morus alba, Taraxacum mongolicum, Scutellaria baicalensis, Pheretima chinensis and Tangerine peel, the Chinese medicine composition prepared with Morus alba, Taraxacum mongolicum, Scutellaria baicalensis, Pheretima chinensis, Tangerine peel, Peucedanum chinense and Pheretima chinensis as raw materials has a significantly higher effect in treating and / or preventing bronchitis than the Chinese medicine composition prepared with Morus alba, Taraxacum mongolicum, Scutellaria baicalensis, Pheretima chinensis and Tangerine peel as raw materials.
[0016] The inventors found in the study that the addition of Peucedanum chinense and Pheretima is very critical; among the Chinese medicinal raw materials of white mulberry bark, dandelion, scutellaria, scutellaria baicalensis and dried tangerine peel, the Chinese medicinal composition prepared by adding only Peucedanum chinense or Pheretima lumbar disc, its therapeutic effect on bronchitis cannot be significantly improved compared with the Chinese medicinal composition prepared by using white mulberry bark, dandelion, scutellaria baicalensis, scutellaria baicalensis and dried tangerine peel as raw materials; among the Chinese medicinal raw materials of white mulberry bark, dandelion, scutellaria baicalensis, scutellaria baicalensis and dried tangerine peel, only the Chinese medicinal composition prepared by adding Peucedanum chinense and Pheretima lumbar disc at the same time, its therapeutic effect on bronchitis can be significantly improved compared with the Chinese medicinal composition prepared by using white mulberry bark, dandelion, scutellaria baicalensis, scutellaria baicalensis and dried tangerine peel as raw materials.
[0017] At the same time, the inventors further discovered in clinical trials that the Chinese medicine composition prepared with Morus alba bark, Taraxacum mongolicum, Scutellaria baicalensis, Gynura sutchuenensis, Citrus reticulata, Peucedanum peucedanum and Pheretima as raw materials also has the effect of treating and / or preventing chronic obstructive pulmonary disease.
[0018] Preferably, the raw material components include the following parts by weight:
[0019] 15-20 parts of mulberry bark, 15-20 parts of dandelion, 12-18 parts of scutellaria, 25-35 parts of golden lock, 8-10 parts of dried tangerine peel, 8-10 parts of peucedanum peucedanum, and 8-10 parts of earthworm.
[0020] Most preferably, the Chinese medicine composition comprises the following raw material components in parts by weight:
[0021] 18 parts of Morus alba bark; 18 parts of Herba Taraxaci; 15 parts of Radix Scutellariae; 30 parts of Rhizoma Chrysanthemi Indici; 9 parts of Pericarpium Citri Reticulatae; 9 parts of Peucedanum pekinensis; 9 parts of Pheretima.
[0022] The present invention also provides a method for preparing the above-mentioned Chinese medicine composition, which comprises the following steps:
[0023] The Chinese medicinal raw materials are mixed, and then the extract is heated and refluxed with a solvent. After the extraction is completed, the extract is concentrated and dried to obtain the Chinese medicinal extract, that is, the Chinese medicinal composition.
[0024] Preferably, the solvent is water or an organic solvent.
[0025] Further preferably, the organic solvent is an ethanol aqueous solution;
[0026] Preferably, the ethanol aqueous solution refers to an ethanol aqueous solution with a volume fraction of 50 to 95%.
[0027] Most preferably, the ethanol aqueous solution refers to an ethanol aqueous solution with a volume fraction of 80%.
[0028] Preferably, the weight of the solvent is 8 to 15 times the total weight of the mixed Chinese medicinal raw materials.
[0029] Most preferably, the weight of the solvent is 12 times the total weight of the mixed Chinese medicinal materials.
[0030] Furthermore, the Chinese medicine extract is loaded onto a silica gel column, and then eluted and impurities are removed using a mixed solvent consisting of n-heptane and ether; then eluted using a mixed solvent consisting of n-heptane and anhydrous ethanol, and after the elution is completed, the eluate eluted with the mixed solvent consisting of n-heptane and anhydrous ethanol is collected, and the Chinese medicine composition is obtained after concentration and drying.
[0031] Preferably, the volume ratio of n-heptane to diethyl ether in the mixed solvent consisting of n-heptane and diethyl ether is 100:15-20.
[0032] Most preferably, the volume ratio of n-heptane to diethyl ether in the mixed solvent consisting of n-heptane and diethyl ether is 100:18.
[0033] Preferably, the volume ratio of n-heptane to anhydrous ethanol in the mixed solvent consisting of n-heptane and anhydrous ethanol is 100:20-25.
[0034] Most preferably, the volume ratio of n-heptane to anhydrous ethanol in the mixed solvent consisting of n-heptane and anhydrous ethanol is 100:23.
[0035] The inventors surprisingly found in further research that the above-mentioned silica gel column elution conditions of the present invention can further enrich a large number of effective ingredients for treating and / or preventing bronchitis, so that the prepared traditional Chinese medicine composition has a much higher effect on treating and / or preventing bronchitis than the traditional Chinese medicine extract that has not been enriched with effective ingredients by silica gel column.
[0036] Here, the inventor requires that the composition of the mixed solvent in the above-mentioned silica gel column elution conditions is very critical; it must first be eluted and impurized with a mixed solvent composed of n-heptane and ether in a volume ratio of 100:15-20, and then eluted with a mixed solvent composed of n-heptane and anhydrous ethanol in a volume ratio of 100:20-25 to obtain a Chinese medicine composition, so that a large amount of effective ingredients for treating and / or preventing bronchitis can be enriched, and the effect of treating and / or preventing bronchitis of the prepared Chinese medicine composition can be further greatly improved. However, the Chinese medicine composition prepared by eluting with other silica gel column elution conditions cannot be enriched with a large amount of effective ingredients for treating and / or preventing bronchitis, and cannot further improve or greatly improve the effect of treating and / or preventing bronchitis of the prepared Chinese medicine composition.
[0037] The present invention also provides an application of the above-mentioned traditional Chinese medicine composition in preparing a medicine for treating and / or preventing bronchitis.
[0038] Preferably, the Chinese medicine composition is used in the preparation of a medicine for treating and / or preventing chronic obstructive pulmonary disease.
[0039] Preferably, the chronic obstructive pulmonary disease is a syndrome of phlegm-heat stagnation in the lungs according to TCM differentiation.
[0040] Preferably, the dosage form of the drug is granules, pills, powders, oral liquids, tablets or capsules.
[0041] Beneficial effects: The present invention provides a Chinese medicine composition with a new composition; the Chinese medicine composition prepared from the Chinese medicine raw material components of the present invention has the effect of treating / or preventing bronchitis; further clinical studies have shown that it also has the effect of treating and / or preventing chronic obstructive pulmonary disease. Therefore, the composition of the present invention is used as an effective ingredient to prepare a drug with the effect of treating / or preventing bronchitis, and / or for preparing a drug with the effect of treating and / or preventing chronic obstructive pulmonary disease, which has important application value.
[0042] In addition, this prescription is well-formulated, contains no expensive or toxic drugs, is safe and reliable, has low technical risks, has broad market demand, and has significant economic and social benefits. DETAILED DESCRIPTION
[0043] The present invention is further explained below with reference to the examples, but the examples do not limit the present invention in any form.
[0044] Example 1 Preparation of Chinese medicine composition
[0045] The Chinese medicinal materials are composed by weight: 18 parts of Morus alba bark; 18 parts of Taraxacum officinale; 15 parts of Scutellaria baicalensis; 30 parts of Golden Lock; 9 parts of Tangerine peel;
[0046] Preparation method: After mixing the above-mentioned Chinese medicinal raw materials, heat them to boiling state with ethanol aqueous solution with a volume fraction of 80% of 12 times the total weight of the mixed Chinese medicinal raw materials, reflux the extract for 1.5 hours, and after the extraction is completed, concentrate and dry the extract to obtain the Chinese medicinal extract, that is, the said Chinese medicinal composition.
[0047] Example 2 Preparation of Chinese medicine composition
[0048] The Chinese medicinal raw materials are composed by weight: 18 parts of Morus alba bark; 18 parts of Taraxacum herb; 15 parts of Scutellaria baicalensis; 30 parts of Golden Lock; 9 parts of Tangerine peel; 9 parts of Peucedanum chinense; 9 parts of Pheretima chinensis;
[0049] Preparation method: After mixing the above-mentioned Chinese medicinal raw materials, heat them to boiling state with ethanol aqueous solution with a volume fraction of 80% of 12 times the total weight of the mixed Chinese medicinal raw materials, reflux the extract for 1.5 hours, and after the extraction is completed, concentrate and dry the extract to obtain the Chinese medicinal extract, that is, the said Chinese medicinal composition.
[0050] Example 3 Preparation of Chinese medicine composition
[0051] The Chinese medicinal raw materials are composed by weight: 18 parts of Morus alba bark; 18 parts of Taraxacum herb; 15 parts of Scutellaria baicalensis; 30 parts of Golden Lock; 9 parts of Tangerine peel; 9 parts of Peucedanum chinense; 9 parts of Pheretima chinensis;
[0052] Preparation method:
[0053] (1) After mixing the above Chinese medicinal materials, heating to boiling state with 12 times the volume fraction of 80% of the total weight of the mixed Chinese medicinal materials with an ethanol aqueous solution, refluxing the extract for 1.5 hours, and concentrating and drying the extract after the extraction to obtain a Chinese medicinal extract;
[0054] (2) The Chinese herbal medicine extract is loaded onto a silica gel column (the silica gel column is filled with 200-300 mesh silica gel of 30 times the weight of the Chinese herbal medicine extract), and then eluted and removed impurities using a mixed solvent consisting of n-heptane and ether in a volume ratio of 100:18 for 5 times the column volume; then eluted using a mixed solvent consisting of n-heptane and anhydrous ethanol in a volume ratio of 100:23 for 8 times the column volume. After the elution is completed, the eluate eluted with the mixed solvent consisting of n-heptane and anhydrous ethanol in a volume ratio of 100:23 is collected, and the Chinese herbal medicine composition is obtained after concentration and drying.
[0055] Example 4 Preparation of Chinese medicine composition
[0056] The Chinese medicinal raw materials are composed by weight: 18 parts of Morus alba bark; 18 parts of Taraxacum herb; 15 parts of Scutellaria baicalensis; 30 parts of Golden Lock; 9 parts of Tangerine peel; 9 parts of Peucedanum chinense;
[0057] Preparation method: After mixing the above-mentioned Chinese medicinal raw materials, heat them to boiling state with ethanol aqueous solution with a volume fraction of 80% of 12 times the total weight of the mixed Chinese medicinal raw materials, reflux the extract for 1.5 hours, and after the extraction is completed, concentrate and dry the extract to obtain the Chinese medicinal extract, that is, the said Chinese medicinal composition.
[0058] The difference between Example 4 and Example 2 is that in Example 4, only Peucedanum chinense is added to Morus alba, Taraxacum mongolicum, Scutellaria baicalensis, Ginseng Root and Tangerine Peel; the Chinese medicine composition is prepared with Morus alba, Taraxacum mongolicum, Scutellaria baicalensis, Ginseng Root, Tangerine Peel and Peucedanum chinense as raw materials; while in Example 2, Peucedanum chinense and Pheretima are added to Morus alba, Taraxacum mongolicum, Scutellaria baicalensis, Ginseng Root and Tangerine Peel, and the Chinese medicine composition is prepared with Morus alba, Taraxacum mongolicum, Scutellaria baicalensis, Ginseng Root, Tangerine Peucedanum and Pheretima chinensis as raw materials.
[0059] Example 5 Preparation of Chinese medicine composition
[0060] The Chinese medicinal materials are composed by weight: 18 parts of mulberry bark; 18 parts of dandelion; 15 parts of scutellaria; 30 parts of golden lock; 9 parts of tangerine peel; 9 parts of earthworm;
[0061] Preparation method: After mixing the above-mentioned Chinese medicinal raw materials, heat them to boiling state with ethanol aqueous solution with a volume fraction of 80% of 12 times the total weight of the mixed Chinese medicinal raw materials, reflux the extract for 1.5 hours, and after the extraction is completed, concentrate and dry the extract to obtain the Chinese medicinal extract, that is, the said Chinese medicinal composition.
[0062] The difference between Example 5 and Example 2 is that in Example 5, only earthworms are added to mulberry bark, dandelion, scutellaria, scutellaria baicalensis and tangerine peel; and the Chinese medicine composition is prepared with mulberry bark, dandelion, scutellaria baicalensis, scutellaria baicalensis, tangerine peel and earthworms as raw materials; while in Example 2, peucedanum chinense and earthworms are added to mulberry bark, dandelion, scutellaria baicalensis, scutellaria baicalensis and tangerine peel, and the Chinese medicine composition is prepared with mulberry bark, dandelion, scutellaria baicalensis, scutellaria baicalensis, tangerine peel, peucedanum chinense and earthworms as raw materials.
[0063] Comparative Example 1 Preparation of Chinese medicine composition
[0064] The Chinese medicinal raw materials are composed by weight: 18 parts of Morus alba bark; 18 parts of Taraxacum herb; 15 parts of Scutellaria baicalensis; 30 parts of Golden Lock; 9 parts of Tangerine peel; 9 parts of Peucedanum chinense; 9 parts of Pheretima chinensis;
[0065] Preparation method:
[0066] (1) After mixing the above Chinese medicinal materials, heating to boiling state with 12 times the volume fraction of 80% of the total weight of the mixed Chinese medicinal materials with an ethanol aqueous solution, refluxing the extract for 1.5 hours, and concentrating and drying the extract after the extraction to obtain a Chinese medicinal extract;
[0067] (2) The Chinese herbal medicine extract is loaded onto a silica gel column (the silica gel column is filled with 200-300 mesh silica gel of 30 times the weight of the Chinese herbal medicine extract), and then eluted and removed impurities using a mixed solvent consisting of n-heptane and ether in a volume ratio of 100:8 for 5 times the column volume; then eluted using a mixed solvent consisting of n-heptane and anhydrous ethanol in a volume ratio of 100:13 for 8 times the column volume. After the elution is completed, the eluate eluted with the mixed solvent consisting of n-heptane and anhydrous ethanol in a volume ratio of 100:13 is collected, and the Chinese herbal medicine composition is obtained after concentration and drying.
[0068] The difference between Comparative Example 1 and Example 3 is that, in Comparative Example 1, impurities are first removed by elution with a mixed solvent consisting of n-heptane and ether in a volume ratio of 100:8, and then the Chinese medicine composition is eluted with a mixed solvent consisting of n-heptane and anhydrous ethanol in a volume ratio of 100:13; while in Example 2, impurities are first removed by elution with a mixed solvent consisting of n-heptane and ether in a volume ratio of 100:18, and then the Chinese medicine composition is eluted with a mixed solvent consisting of n-heptane and anhydrous ethanol in a volume ratio of 100:23.
[0069] Comparative Example 2 Preparation of Chinese medicine composition
[0070] The Chinese medicinal raw materials are composed by weight: 18 parts of Morus alba bark; 18 parts of Taraxacum herb; 15 parts of Scutellaria baicalensis; 30 parts of Golden Lock; 9 parts of Tangerine peel; 9 parts of Peucedanum chinense; 9 parts of Pheretima chinensis;
[0071] Preparation method:
[0072] (1) After mixing the above Chinese medicinal materials, heating to boiling state with 12 times the volume fraction of 80% of the total weight of the mixed Chinese medicinal materials with an ethanol aqueous solution, refluxing the extract for 1.5 hours, and concentrating and drying the extract after the extraction to obtain a Chinese medicinal extract;
[0073] (2) The Chinese herbal medicine extract is loaded onto a silica gel column (the silica gel column is filled with 200-300 mesh silica gel of 30 times the weight of the Chinese herbal medicine extract), and then eluted and removed impurities using a mixed solvent consisting of n-heptane and anhydrous ethanol in a volume ratio of 100:25 for 5 times the column volume; then eluted using a mixed solvent consisting of n-heptane and anhydrous ethanol in a volume ratio of 100:40 for 8 times the column volume. After the elution is completed, the eluate eluted with the mixed solvent consisting of n-heptane and anhydrous ethanol in a volume ratio of 100:40 is collected, and the Chinese herbal medicine composition is obtained after concentration and drying.
[0074] The difference between Comparative Example 2 and Example 3 is that, in Comparative Example 2, impurities are first removed by elution with a mixed solvent consisting of n-heptane and anhydrous ethanol in a volume ratio of 100:25, and then the Chinese medicine composition is eluted with a mixed solvent consisting of n-heptane and anhydrous ethanol in a volume ratio of 100:40; while in Example 2, impurities are first removed by elution with a mixed solvent consisting of n-heptane and ether in a volume ratio of 100:18, and then the Chinese medicine composition is eluted with a mixed solvent consisting of n-heptane and anhydrous ethanol in a volume ratio of 100:23.
[0075] Experimental Example 1 Experiment on the treatment and / or prevention of bronchitis
[0076] Method for establishing chronic bronchitis model mice: KM mice weighing 20±2g were selected, and lipopolysaccharide was injected into the respiratory tract of the mice on the 1st day and the 15th day; the mice were fumigated starting from the 2nd day, and the fumigation lasted for 30 days, 30 minutes per day, and the chronic bronchitis model mice were established after the fumigation.
[0077] 160 chronic bronchitis model mice were selected and randomly divided into 8 groups, each with 20 mice, half male and half female; divided into experimental groups 1 to 7 and a model control group; experimental groups 1 to 7 were given 100 mg·kg -1 ·d -1 The Chinese medicine composition prepared in Examples 1 to 5 and Comparative Examples 1 to 2 was intragastrically administered with a dosage of ; the model control group was intragastrically administered with an equal amount of distilled water every day; after continuous intragastrically administering the drug for 14 days, the concentrations of TNF-α and IL-8 in the bronchoalveolar lavage fluid of the mice were tested; the test results are shown in Table 1.
[0078] Table 1 Results of experiments on the treatment and / or prevention of bronchitis
[0079]
[0080] It can be seen from the experimental data in Table 1 that the concentrations of TNF-α and IL-8 in the experimental group 1 are lower than those in the model group; this indicates that the traditional Chinese medicine composition prepared with Morus alba bark, Taraxacum mongolicum, Scutellaria baicalensis, Glehnia littoralis and Citrus reticulata as raw materials has the effect of treating and / or preventing bronchitis.
[0081] It can also be seen from the experimental data in Table 1 that the concentrations of TNF-α and IL-8 in experimental group 2 (testing the Chinese medicine composition prepared in Example 2) were further significantly reduced compared with those in experimental group 1 (testing the Chinese medicine composition prepared in Example 1); this indicates that the Chinese medicine composition prepared with mulberry bark, dandelion, scutellaria, scutellaria baicalensis, scutellaria chinensis and tangerine peel, by adding peucedanum and earthworm, and using mulberry bark, dandelion, scutellaria baicalensis, scutellaria chinensis, tangerine peel, peucedanum and earthworm as raw materials, has a significantly higher effect in treating and / or preventing bronchitis than the Chinese medicine composition prepared with mulberry bark, dandelion, scutellaria baicalensis, scutellaria chinensis and tangerine peel as raw materials.
[0082] However, the concentrations of TNF-α and IL-8 in experimental group 4 (testing the Chinese medicine composition prepared in Example 4) and experimental group 5 (testing the Chinese medicine composition prepared in Example 5) were not significantly reduced compared with experimental group 1 (testing the Chinese medicine composition prepared in Example 1), and the reduction in the concentrations of TNF-α and IL-8 was much smaller than that in experimental group 2. This shows that the addition of Peucedanum chinense and Pheretima is very critical; among the Chinese medicinal raw materials Morus alba, Taraxacum, Scutellaria baicalensis, Cyperus rotundus and Tangerine peel, the Chinese medicinal composition prepared by adding only Peucedanum chinense or Pheretima lum, its therapeutic and / or preventive bronchitis effect is not significantly improved compared with the Chinese medicinal composition prepared by using Morus alba, Taraxacum, Scutellaria baicalensis, Cyperus rotundus and Tangerine peel as raw materials; among the Chinese medicinal raw materials Morus alba, Taraxacum, Scutellaria baicalensis, Cyperus rotundus and Tangerine peel, only the Chinese medicinal composition prepared by adding Peucedanum chinense and Pheretima lum at the same time, its therapeutic and / or preventive bronchitis effect can be significantly improved compared with the Chinese medicinal composition prepared by using Morus alba, Taraxacum, Scutellaria baicalensis, Cyperus rotundus and Tangerine peel as raw materials. Peucedanum chinense and earthworm are added to the Chinese medicinal raw materials of mulberry bark, dandelion, scutellaria baicalensis, kaempferia lobata and tangerine peel at the same time; the therapeutic and / or preventive effects of the Chinese medicinal composition prepared with mulberry bark, dandelion, scutellaria baicalensis, kaempferia lobata and tangerine peel as raw materials can be synergistically improved.
[0083] It can also be seen from the experimental data in Table 1 that the concentrations of TNF-α and IL-8 in experimental group 3 (testing the Chinese medicine composition prepared in Example 3) were further significantly reduced compared with those in experimental group 2 (testing the Chinese medicine composition prepared in Example 2); this indicates that the Chinese medicine extract obtained by ethanol extraction with Morus alba, Taraxacum mongolicum, Scutellaria baicalensis, Gynura sutchumae, Citrus reticulata, Peucedanum peucedanum and Pheretima as raw materials, and further prepared by the above-mentioned silica gel column elution conditions of the present invention, has a further significantly higher effect on treating and / or preventing bronchitis than the Chinese medicine extract whose effective ingredients have not been enriched by the silica gel column.
[0084] However, the concentrations of TNF-α and IL-8 in experimental group 6 (testing the Chinese medicine composition prepared in comparative example 1) and experimental group 7 (testing the Chinese medicine composition prepared in comparative example 2) were not significantly reduced or decreased relative to experimental group 2 (testing the Chinese medicine composition prepared in Example 2); this specification: In the elution conditions of the silica gel column of the present invention, it is necessary to first elute and remove impurities with a mixed solvent consisting of n-heptane and ether in a volume ratio of 100:15-20, and then elute the obtained Chinese medicine composition with a mixed solvent consisting of n-heptane and anhydrous ethanol in a volume ratio of 100:20-25, in order to further significantly improve the therapeutic and / or preventive effects of the prepared Chinese medicine composition on bronchitis. However, the Chinese medicine composition prepared by eluting with other silica gel column elution conditions cannot further improve or significantly improve the therapeutic and / or preventive effects of the prepared Chinese medicine composition on bronchitis.
[0085] Example 6 Preparation of granules
[0086] The Chinese medicine composition prepared in Example 2 was taken as an effective ingredient, and then prepared into pharmaceutical granules by conventional methods; wherein the mass fraction of the Chinese medicine composition prepared in Example 2 in the granules was 10%.
[0087] Example 7 Preparation of granules
[0088] The Chinese medicine composition prepared in Example 3 was taken as an effective ingredient, and then prepared into pharmaceutical granules by conventional methods; wherein the mass fraction of the Chinese medicine composition prepared in Example 3 in the granules was 10%.
[0089] Example 8 Preparation of Pills
[0090] The Chinese medicine composition prepared in Example 2 was taken as an effective ingredient, and then prepared into pharmaceutical pills by conventional methods; wherein the mass fraction of the Chinese medicine composition prepared in Example 2 in the pills was 10%.
[0091] Example 9 Preparation of capsules
[0092] The Chinese medicine composition prepared in Example 3 was taken as an effective ingredient, and then prepared into a pharmaceutical capsule by a conventional method; wherein the mass fraction of the Chinese medicine composition prepared in Example 3 in the capsule was 10%.
[0093] Example 10 Preparation of tablets
[0094] The Chinese medicine composition prepared in Example 3 was taken as an effective ingredient, and then prepared into pharmaceutical tablets by conventional methods; wherein the mass fraction of the Chinese medicine composition prepared in Example 3 in the tablets was 10%.
[0095] Experimental Example 2 Clinical Experiment
[0096] Experimental subjects: Clinically diagnosed with chronic obstructive pulmonary disease, and TCM syndrome of phlegm-heat stagnation in the lungs.
[0097] Grouping: Divided into a treatment group and a control group; 55 cases in the treatment group and 53 cases in the control group. The treatment group took the Chinese medicine composition granules prepared in Example 6 every day; taken with boiled water, twice a day, 30g each time, for 10 consecutive days. The control group took the following drugs: Qingfei granule simulation agent; taken with boiled water, twice a day, 30g each time, for 14 consecutive days.
[0098] The clinical trial results and data are shown in Tables 2 to 10; it can be seen from the clinical trial results and data in Tables 2 to 10 that the Chinese medicine composition of the present invention has excellent effect in treating chronic obstructive pulmonary disease (phlegm-heat stagnation in the lungs).
[0099] 1. Comparison of total scores of TCM syndromes
[0100] As shown in Table 2, after treatment, the total TCM syndrome scores of the patients were (45.00±52.38) points in the treatment group and (76.71±86.60) points in the control group, respectively. The data of the two groups were normally distributed, and the t-test showed that p=0.011﹤0.05.
[0101] Table 2 Comparison of total scores of TCM syndromes before and after treatment (unit: points)
[0102]
[0103] 2. Comparison of main symptom scores
[0104] As shown in Table 3, Mann-Whitney U rank sum test showed that the two groups were compared within the group before and after treatment, p < 0.05; the two groups were compared between the two groups after treatment, *P < 0.05.
[0105] Table 3 Comparison of main symptom scores before and after treatment (unit: points)
[0106]
[0107] 3. Comparison of sub-symptom scores
[0108] As shown in Table 4, Mann-Whitney U rank sum test showed that the two groups were compared within the group before and after treatment, p < 0.05; the two groups were compared between the two groups after treatment, *P > 0.05.
[0109] Table 4 Comparison of symptom scores before and after treatment (unit: points)
[0110]
[0111] 4. Comparison of therapeutic effects on lung rales
[0112] As shown in Table 5, the effective rate of the treatment group was 83.64%, and the effective rate of the control group was 66.04%; the efficacy of lung rales in the two groups was tested by chi-square test, p = 0.035﹤0.05.
[0113] Table 5 Comparison of therapeutic effects on lung rales
[0114]
[0115] 5. Comparison of TCM Syndrome Therapy
[0116] As shown in Table 6, the TCM syndrome efficacy of the treatment group was 90.91%, and the TCM syndrome efficacy of the control group was 73.58%; the difference in TCM syndrome efficacy between the two groups was statistically significant (p=0.018﹤0.05).
[0117] Table 6 Comparison of efficacy of TCM syndromes
[0118]
[0119] 6. Comparison of mMRC scores before and after treatment
[0120] As shown in Table 7, Mann-Whitney U rank sum test showed that the two groups were compared within the group before and after treatment, p < 0.05; the two groups were compared between the two groups after the end of treatment, *p < 0.05.
[0121] Table 7 Comparison of mMRC scores between the two groups before and after treatment
[0122]
[0123] 7. Comparison of CAT scores before and after treatment
[0124] As shown in Table 8, Mann-Whitney U rank sum test showed that the two groups were compared within the group before and after treatment, p < 0.05; the two groups were compared between the two groups after the end of treatment, *p < 0.05.
[0125] Table 8 Comparison of CAT scores between the two groups of patients before and after treatment
[0126]
[0127] 8. Comparison of serum IL-6, IL-8, and TNF-α levels before and after treatment
[0128] As shown in Table 9, Mann-Whitney U rank sum test showed that the two groups were compared within the group before and after treatment, p < 0.05; the two groups were compared between the two groups after the end of treatment, *p < 0.05.
[0129] Table 9 Comparison of serum IL-6, IL-8, and TNF-α levels between the two groups of patients before and after treatment (unit: pg / ml)
[0130]
[0131] 10. Comparison of peripheral blood TLR2 and TLR4 levels before and after treatment
[0132] As shown in Table 10, the Mann-Whitney U rank sum test showed that the two groups were compared within the group before and after treatment, and p was < 0.05; the t test showed that the two groups were compared between the groups after the treatment, *p < 0.05.
[0133] Table 10 Comparison of peripheral blood TLR2 and TLR4 levels between the two groups of patients before and after treatment (unit: pg / ml)
[0134]
Claims
1. A Chinese medicine composition, It is characterized in that Made from the following raw material components in parts by weight: 15-20 parts of mulberry bark; 15-20 parts of dandelion; 12-18 parts of scutellaria; 25-35 parts of golden lock; 8-10 parts of dried orange peel; 8-10 parts of peucedanum; 8-10 parts of earthworm; The method for preparing the Chinese medicine composition is characterized by comprising the following steps: After mixing the Chinese medicinal raw materials, the extract is heated and refluxed with a solvent, and after the extraction is completed, the extract is concentrated and dried to obtain a Chinese medicinal extract; the solvent is an ethanol aqueous solution with a volume fraction of 80%; The Chinese medicine extract is loaded onto a silica gel column, and then eluted and impurities are removed using a mixed solvent consisting of n-heptane and ether; then eluted using a mixed solvent consisting of n-heptane and anhydrous ethanol, and after the elution is completed, the eluate eluted with the mixed solvent consisting of n-heptane and anhydrous ethanol is collected, and concentrated and dried to obtain the Chinese medicine composition; The volume ratio of n-heptane to diethyl ether in the mixed solvent composed of n-heptane and diethyl ether is 100:15-20; The volume ratio of n-heptane to anhydrous ethanol in the mixed solvent composed of n-heptane and anhydrous ethanol is 100:20-25.
2. The Chinese medicine composition according to claim 1, It is characterized in that Made from the following raw material components in parts by weight: 18 parts of Morus alba bark; 18 parts of Herba Taraxaci; 15 parts of Radix Scutellariae; 30 parts of Rhizoma Chrysanthemi Indici; 9 parts of Pericarpium Citri Reticulatae; 9 parts of Peucedanum pekinensis; 9 parts of Pheretima.
3. Use of the Chinese medicine composition according to any one of claims 1 to 2 in the preparation of a medicament for treating and / or preventing bronchitis.
4. Use of the Chinese medicine composition according to any one of claims 1 to 2 in the preparation of a medicament for treating and / or preventing chronic obstructive pulmonary disease.
5. The use according to claim 3 or 4, It is characterized in that The dosage form of the medicine is granules, pills, powders, oral liquids, tablets or capsules.
